Particle.news

Pomegranate‑Derived Molecule Shows Promise for Hard‑To‑Treat Heart Failure

Preclinical tests link the microbiome product urolithin A to a PKGI‑alpha pathway that eased heart stiffness and scarring while human benefit remains unproven.

Overview

  • Researchers at King’s College London reported that urolithin A improved heart muscle relaxation, reduced fibrosis, and limited pathological enlargement in lab models.
  • The team traced the effect to activation of a PKGI‑alpha–related protein pathway, with the compound reacting at a specific amino acid to trigger improved tissue relaxation.
  • Findings come from experiments in animal models and engineered human heart tissue made from stem cells rather than from clinical trials in patients.
  • Urolithin A is produced when gut bacteria break down compounds in pomegranates, walnuts, and some berries and has prior human safety data but no proven effectiveness for HFpEF.
  • The study was published in Science Advances and funded by the British Heart Foundation, and researchers say targeted clinical trials are the next step before any treatment claims can be made.